Jim DeTore serves as Chief Financial Officer at CG Oncology, Inc., a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). With more than 25 years of experience in finance and accounting within the life sciences industry, DeTore has a distinguished track record of leading high-growth biotech companies through critical milestones, including initial public offerings, strategic financings, and transformative acquisitions. His expertise in capital markets, investor relations, and operational finance positions him as a key architect of CG Oncology's financial strategy amid its Phase 3 clinical advancements and path to potential commercialization. Prior to joining CG Oncology in 2023, DeTore held successive CFO roles at Liquidia Corporation (2020-2023), where he oversaw financial operations during product launches and FDA approvals; Akebia Therapeutics (2018-2020), managing significant debt financings and pipeline development; and Synageva BioPharma (2012-2015), playing a pivotal role in its 2012 NASDAQ IPO and $8.4 billion acquisition by Alexion Pharmaceuticals. Earlier in his career, he held senior finance positions at Genzyme Corporation and other life sciences firms, building a foundation in financial planning, SEC reporting, and M&A transactions. At CG Oncology, DeTore directs all aspects of financial management, including budgeting, treasury, risk assessment, and capital allocation to support the ongoing BOND-003 pivotal trial and preparations for regulatory submission. His leadership has strengthened the company's balance sheet through efficient fundraising and cost discipline, enabling CG Oncology to advance its mission of delivering a potential first-in-class therapy for BCG-unresponsive NMIBC patients.